➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Express Scripts
McKesson
Harvard Business School
Baxter

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,309,569


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,309,569 protect, and when does it expire?

Patent 8,309,569 protects XIFAXAN and is included in one NDA.

This patent has thirty patent family members in fifteen countries.

Summary for Patent: 8,309,569
Title:Methods for treating diarrhea-associated irritable bowel syndrome
Abstract: The present invention provides methods of treating diarrhea-associated irritable bowel syndrome (IBS-D) following rifaximin administration.
Inventor(s): Forbes; William (Raleigh, NC), Johnson; Lorin (Palo Alto, CA)
Assignee: Salix Pharmaceuticals, Ltd. (Raleigh, NC)
Application Number:12/393,979
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,309,569
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,309,569

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF. ⤷  Free Forever Trial
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS. ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,309,569

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009219240 ⤷  Free Forever Trial
Australia 2010292043 ⤷  Free Forever Trial
Brazil 112012005627 ⤷  Free Forever Trial
Brazil PI0908026 ⤷  Free Forever Trial
Canada 2716578 ⤷  Free Forever Trial
Canada 2773982 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Johnson and Johnson
Dow
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.